Current therapy for hepatitis C
- 21 September 2005
- journal article
- review article
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 22 (4) , 341-349
- https://doi.org/10.1007/s00384-005-0038-9
Abstract
Pegylated interferon alfa in combination with ribavirin has been established as standard therapy for chronic hepatitis C virus (HCV) infection with sustained virologic response rates of 54–63%. The duration of therapy depends on the HCV genotype with currently 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3.Keywords
This publication has 50 references indexed in Scilit:
- Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis CJournal of Hepatology, 2005
- Prophylactic SSRI during interferon alpha re‐therapy in patients with chronic hepatitis C and a history of interferon‐induced depressionJournal of Viral Hepatitis, 2005
- 93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled studyJournal of Hepatology, 2004
- 511 Evaluation of a new, highly sensitive, real time PCR based assay for quantification of HCV RNAJournal of Hepatology, 2004
- Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearanceJournal of Hepatology, 2004
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis CJournal of Hepatology, 2003
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002Hepatology, 2002
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986